Danaparoid sodium
Orgaran (danaparoid sodium) is an unknown pharmaceutical. Danaparoid sodium was first approved as Orgaran on 1996-12-24. It is used to treat pulmonary embolism, thrombocytopenia, thromboembolism, and venous thrombosis in the USA. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Danaparoid sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ORGARAN | Aspen Global | N-020430 DISCN | 1996-12-24 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Danaparoid sodium |
| INN | danaparoid sodium |
| Description | Orgaran (danaparoid sodium) is an unknown pharmaceutical. Danaparoid sodium was first approved as Orgaran on 1996-12-24. It is used to treat pulmonary embolism, thrombocytopenia, thromboembolism, and venous thrombosis in the USA. The pharmaceutical is active against antithrombin-III. |
| Classification | Small molecule |
| Drug class | antithrombotics (heparinoid type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 308068-55-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201534 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06754 |
| UNII ID | 5004UU3156 (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
730 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use